Intervention mechanism of Yiqi Fumai Formula in mice with experimental heart failure based on "heart-gut axis".
10.19540/j.cnki.cjcmm.20250202.203
- Author:
Zi-Xuan ZHANG
1
;
Yu-Zhuo WU
2
;
Ke-Dian CHEN
3
;
Jian-Qin WANG
4
;
Yang SUN
2
;
Yin JIANG
5
;
Yi-Xuan LIN
6
;
He-Rong CUI
4
;
Hong-Cai SHANG
7
Author Information
1. Dongfang Hospital, Beijing University of Chinese Medicine Beijing 100078, China School of Life Sciences, Beijing University of Chinese Medicine Beijing 102488, China.
2. Dongzhimen Hospital, Beijing University of Chinese Medicine Beijing 100700, China.
3. Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences Beijing 100700, China.
4. School of Life Sciences, Beijing University of Chinese Medicine Beijing 102488, China.
5. Institute of Clinical Basic Medicine, China Academy of Chinese Medical Sciences Beijing 100700, China.
6. School of Chinese Materia Medica, Beijing University of Chinese Medicine Beijing 102488, China.
7. Dongfang Hospital, Beijing University of Chinese Medicine Beijing 100078, China Key Laboratory of Chinese Internal Medicine of Ministry of Education,Beijing University of Chinese Medicine Beijing 100029, China.
- Publication Type:Journal Article
- Keywords:
16S rDNA;
PI3K-Akt;
Yiqi Fumai Formula;
heart failure;
heart-gut axis
- MeSH:
Animals;
Drugs, Chinese Herbal/administration & dosage*;
Heart Failure/microbiology*;
Mice;
Mice, Inbred BALB C;
Male;
Disease Models, Animal;
Gastrointestinal Microbiome/drug effects*;
Heart/physiopathology*;
Humans;
Signal Transduction/drug effects*
- From:
China Journal of Chinese Materia Medica
2025;50(12):3399-3412
- CountryChina
- Language:Chinese
-
Abstract:
This paper aimed to investigate the therapeutic effect and mechanism of action of the Yiqi Fumai Formula(YQFM), a kind of traditional Chinese medicine(TCM), on mice with experimental heart failure based on the "heart-gut axis" theory. Based on the network pharmacology integrated with the group collaboration algorithm, the active ingredients were screened, a "component-target-disease" network was constructed, and the potential pathways regulated by the formula were predicted and analyzed. Next, the model of experimental heart failure was established by intraperitoneal injection of adriamycin at a single high dose(15 mg·kg~(-1)) in BALB/c mice. After intraperitoneal injection of YQFM(lyophilized) at 7.90, 15.80, and 31.55 mg·d~(-1) for 7 d, the protective effects of the formula on cardiac function were evaluated using indicators such as ultrasonic electrocardiography and myocardial injury markers. Combined with inflammatory factors in the cardiac and colorectal tissue, as well as targeted assays, the relevant indicators of potential pathways were verified. Meanwhile, 16S rDNA sequencing was performed on mouse fecal samples using the Illumina platform to detect changes in gut flora and analyze differential metabolic pathways. The results show that the administration of injectable YQFM(lyophilized) for 7 d significantly increased the left ventricular end-systolic internal diameter, fractional shortening, and ejection fraction of cardiac tissue of mice with experimental heart failure(P<0.05). Moreover, markers of myocardial injury were significantly decreased(P<0.05), indicating improved cardiac function, along with significantly suppressed inflammatory responses in cardiac and intestinal tissue(P<0.05). Additionally, the species of causative organisms was decreased, and the homeostasis of gut flora was improved, involving a modulatory effect on PI3K-Akt signaling pathway-related inflammation in cardiac and colorectal tissue. In conclusion, YQFM can affect the "heart-gut axis" immunity through the homeostasis of the gut flora, thereby exerting a therapeutic effect on heart failure. This finding provides a reference for the combination of TCM and western medicine to prevent and treat heart failure based on the "heart-gut axis" theory.
